Novo Nordisk A/S which can be found using ticker (NVO) have now 5 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 194.58 and 119.74 calculating the mean target price we have $160.91. Given that the stocks previous close was at $165.03 this would indicate that there is a downside of -2.5%. There is a 50 day moving average of $149.49 and the 200 day MA is $124.69. The market cap for the company is $372,375m. Visit the company website at: https://www.novonordisk.com
The potential market cap would be $363,079m based on the market consensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
The company has a dividend yield of 1.07% with the ex dividend date set at 24-3-2023 (DMY).
Other points of data to note are a P/E ratio of 46.19, revenue per share of 78.12 and a 21.69% return on assets.
